TEVA-TRAZODONE 100 MG
TRAZODONE HYDROCHLORIDE : 100 MG · DIN 02144271 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-TRAZODONE?
TEVA-TRAZODONE 100 MG contains TRAZODONE HYDROCHLORIDE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02144271, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 15-Jun-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-TRAZODONE used for?
Symptomatic relief of depressive illness.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02144271 |
|---|---|
| Brand name | TEVA-TRAZODONE |
| Generic / active ingredient | TRAZODONE HYDROCHLORIDE : 100 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AX05 TRAZODONE |
| AHFS class | 28:16.04.24 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Jun-2011 |
| Original market date | 1995-01-18 00:00:00 |
How is it administered?
Initial: 150-200 mg/day in divided doses after meals. Increase by 50 mg increments up to 300 mg/day. Max 400-600 mg/day in hospitalized patients. Elderly: use half adult dose.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15-30°C and protect from light. Unit dose strips: 15-25°C, protect from light and high humidity.
How is it supplied?
Bottles of 100, 500, and 1000 tablets; unit dose strips of 100.
Contraindications
Known hypersensitivity to trazodone.
Warnings and precautions
Risk of priapism (may require surgery); arrhythmogenic potential (monitor cardiac patients); angle-closure glaucoma; potential for suicide ideation; may impair ability to drive/operate machinery.
Is TRAZODONE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANIS HEALTH INC (Tier 3 Drug Shortages About & Resources), last seen 19 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N06AX05 TRAZODONE. 21 of 57 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-TRAZODONE | 100 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02537915 |
| AG-TRAZODONE | 150 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02537923 |
| AG-TRAZODONE | 50 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02537907 |
| APO-TRAZODONE D TABLETS 150MG | 150 MG | TABLET | APOTEX INC | MARKETED | DIN 02147653 |
| APO-TRAZODONE TABLETS 100MG | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02147645 |
| APO-TRAZODONE TABLETS 50MG | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02147637 |
| JAMP TRAZODONE | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02442817 |
| JAMP TRAZODONE | 150 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02442825 |
| JAMP TRAZODONE | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02442809 |
| PMS TRAZODONE HCL TAB 100MG | 100 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 01937235 |
Who else supplies TRAZODONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TRAZODONE appears in 36 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.